With Hologic, Inc. HOLX gearing up to release its fiscal 2025 first-quarter financial results on Feb. 5 after the market ...

Hologic HOLX is set to release first-quarter fiscal 2025 results on Feb. 5 after the closing bell. Stay up-to-date with all ...

The U.S. Food and Drug Administration has sent a warning letter to Marlborough, Mass.-based medical technology company ...

Hologic is down approximately 20% from recent highs and continues to grow organically and via a series of 'bolt-on' ...

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store. Hologic stopped manufacturing the device after ...

Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Hologic in a research note issued on ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Hologic Inc. has received a warning letter from the Food and Drug Administration regarding its BioZorb product line, even though the company recalled the devices last year.

Piero Cingari FDA Warns Hologic Over BioZorb Manufacturing Violations FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on HOLX stock, giving a Buy rating on January 13.Stay Ahead of the ...

The approach utilizes robust cash flows to add products that leverage its existing channel strength and accelerate growth. Each of Hologic’s core franchises has multiple durable growth drivers ...

Hologic has not yet completed its financial ... and revenues from discontinued products. The Company defines its non-GAAP EPS and other non-GAAP financial measures to exclude, as applicable ...